Streetbeat News

Analyst Ratings

CVX

JP Morgan analyst John M Royall upgraded Chevron Corp (NYSE:CVX) to Neutral from Underweight, raising the price target to $170 from $161. Royall is bullish on CVX's defensive balance sheet, low net debt to capital, and cash in hand of over $15B. The company's solid financial position is expected to support its capital program and share repurchase program.

Portfolio Pulse from Lekha Gupta

May 31, 2023 | 4:39 pm

BIG

Goldman Sachs analyst Kate McShane maintains a Sell rating on Big Lots (NYSE:BIG) and lowers the price target from $14 to $5.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 4:39 pm

BOWL

Roth MKM analyst Eric Handler reiterates a Buy rating on Bowlero (NYSE:BOWL) and maintains a $17 price target.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 4:35 pm

OCEA

Taglich Brothers analyst Howard Halpern initiates coverage on Ocean Biomedical (NASDAQ:OCEA) with a Speculative Buy rating and announces a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 4:33 pm

MELI

A whale has taken a bearish stance on MercadoLibre (NASDAQ:MELI), with 61% of detected unusual options trades being bearish. Whales have been targeting a price range of $1,000 to $2,000 for MercadoLibre over the last 3 months. Major banks maintain positive ratings on the stock.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 4:32 pm

QCOM

Unusual options activity has been observed for Qualcomm (NASDAQ:QCOM), with 70% of investors taking a bearish stance. Whales have targeted a price range of $65 to $150 for Qualcomm over the last 3 months. The stock is currently down 2.9% at $112.64.

Portfolio Pulse from Benzinga Insights

May 31, 2023 | 4:31 pm

CGAU

TD Securities analyst Steven Green has upgraded Centerra Gold (NYSE:CGAU) from Hold to Buy and raised the price target from C$8.5 to C$11.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 4:31 pm

CGAU

Raymond James analyst Brian MacArthur upgraded Centerra Gold (NYSE:CGAU) from Market Perform to Outperform and announced an $11 price target.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 4:28 pm

FRLN

HC Wainwright & Co. analyst Patrick Trucchio reiterated a Buy rating on Freeline Therapeutics (NASDAQ:FRLN) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 4:24 pm

BODY

DA Davidson analyst Linda Bolton Weiser maintains a Buy rating on Beachbody Co (NYSE: BODY) but lowers the price target from $2 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2023 | 4:19 pm